Charles River Laboratories Announces First-Quarter 2021 Results

Logo
May 4, 2021 11:00 UTC

 

– First-Quarter Revenue of $824.6 Million –

– First-Quarter GAAP Earnings per Share of $1.20 and Non-GAAP Earnings per Share of $2.53 –

– Updates 2021 Guidance –

 

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2021. For the quarter, revenue was $824.6 million, an increase of 16.6% from $707.1 million in the first quarter of 2020.

Acquisitions contributed 0.7% to consolidated first-quarter revenue growth. The impact of foreign currency translation benefited reported revenue growth by 2.9%. Excluding the effect of these items, organic revenue growth of 13.0% was driven by contributions from all three business segments. The year-over-year comparison to last year’s COVID-19-related revenue impact contributed approximately 140 basis points to the reported and organic revenue growth rates in the first quarter, principally in the Research Models and Services segment.

On a GAAP basis, first-quarter net income attributable to common shareholders was $61.5 million, an increase of 21.2% from net income of $50.8 million for the same period in 2020. First-quarter diluted earnings per share on a GAAP basis were $1.20, an increase of 17.6% from $1.02 for the first quarter of 2020. The increases in the GAAP net income and earnings per share were driven primarily by higher revenue and operating margin improvement, partially offset by debt extinguishment costs and the write-off of deferred financing costs related to debt refinancing activities in the first quarter of 2021.

On a non-GAAP basis, net income from continuing operations was $129.2 million for the first quarter of 2021, an increase of 40.7% from $91.8 million for the same period in 2020. First‑quarter diluted earnings per share on a non-GAAP basis were $2.53, an increase of 37.5% from $1.84 per share for the first quarter of 2020. The non-GAAP net income and earnings per share increases were driven primarily by higher revenue and operating margin improvement.

James C. Foster, Chairman, President and Chief Executive Officer, said, “Our first-quarter performance demonstrates the power of our unique, non-clinical portfolio and the strength of the biopharmaceutical market environment. A global focus on scientific innovation is driving record levels of investment in the biopharmaceutical industry, which is generating biomedical breakthroughs across multiple therapeutic areas at a rapid pace. We believe these factors are resulting in unprecedented client demand across most of our businesses.”

 

“To maintain and enhance our position as the leading, non-clinical CRO, we are strategically expanding our portfolio and enhancing our scientific capabilities, especially in the use of more complex research techniques and advanced drug modalities such as cell and gene therapies. These investments are enabling us to offer greater value to our clients and capitalize on the significant growth opportunities,” Mr. Foster concluded.

First-Quarter Segment Results

Research Models and Services (RMS)

Revenue for the RMS segment was $176.9 million in the first quarter of 2021, an increase of 21.2% from $146.0 million in the first quarter of 2020. The impact of foreign currency translation contributed 4.2%, and acquisitions, principally Cellero which was completed in August 2020, contributed 2.2% to first-quarter RMS revenue. Organic revenue growth of 14.8% was driven by robust demand for research models in China, as well as higher revenue for research models services, particularly Genetically Engineered Models and Services (GEMS). The year-over-year comparison to last year’s COVID-19-related revenue impact contributed approximately 620 basis points to the RMS revenue growth rate in the first quarter.

In the first quarter of 2021, the RMS segment’s GAAP operating margin increased to 25.4% from 18.7% in the first quarter of 2020. On a non-GAAP basis, the operating margin increased to 28.7% from 23.0% in the first quarter of 2020. The GAAP and non-GAAP operating margin increases were driven primarily by operating leverage from higher sales volume for research models.

Discovery and Safety Assessment (DSA)

Revenue for the DSA segment was $501.2 million in the first quarter of 2021, an increase of 14.2% from $438.7 million in the first quarter of 2020. The impact of foreign currency translation contributed 2.3% to DSA revenue growth. Organic revenue growth of 11.6% was primarily driven by robust demand from global biopharmaceutical and biotechnology clients in both the Discovery Services and Safety Assessment businesses.

In the first quarter of 2021, the DSA segment’s GAAP operating margin increased to 18.1% from 16.5% in the first quarter of 2020. On a non-GAAP basis, the operating margin increased to 23.8% from 22.0% in the first quarter of 2020. The GAAP and non-GAAP operating margin increases were driven primarily by operating leverage from higher revenue in both the Discovery Services and Safety Assessment businesses.

 

Manufacturing Support (Manufacturing)

Revenue for the Manufacturing segment was $146.5 million in the first quarter of 2021, an increase of 19.7% from $122.4 million in the first quarter of 2020. The impact of foreign currency translation contributed 4.1% to Manufacturing revenue growth. Organic revenue growth of 15.6% was driven by strong demand in the Biologics Testing Solutions (Biologics) and Microbial Solutions businesses.

In the first quarter of 2021, the Manufacturing segment’s GAAP operating margin increased slightly to 33.8% from 33.6% in the first quarter of 2020. On a non-GAAP basis, the operating margin decreased slightly to 35.5% from 35.6% in the first quarter of 2020.

2021 Guidance

On February 17, 2021, the Company provided 2021 financial guidance, both excluding and including the impact of the Cognate BioServices acquisition. The acquisition of Cognate was subsequently completed on March 29, 2021.

The Company is increasing its revenue growth and non-GAAP earnings per share guidance for 2021, as a result of the stronger-than-expected first quarter financial performance and an expectation that robust client demand trends will continue for the remainder of the year. This updated guidance includes the acquisitions that have already been completed in 2021, including Cognate.

The Company’s updated guidance for revenue growth, earnings per share, and free cash flow is as follows:

2021 GUIDANCE INCLUDING COGNATE

CURRENT

PRIOR

Revenue growth, reported

19% – 21%

16% – 18%

Less: Contribution from acquisitions (1)

(4.5%) – (5.0%)

(4.5%) – (5.0%)

Unfavorable/(favorable) impact of foreign exchange

~(2.5%)

(2.0%) – (2.5%)

Revenue growth, organic (2)

12% – 14%

9% – 11%

GAAP EPS estimate

$5.95 – $6.20

Acquisition-related amortization (3)

$2.15 – $2.40

Acquisition-related adjustments (4)

$0.75 – $0.80

Other items (5)

~$0.55

Venture capital and other strategic investment losses/(gains), net (6)

$0.25

Non-GAAP EPS estimate

$9.75 – $10.00

$9.00 – $9.25

Free cash flow (7)

~$435 million

 
Footnotes to Guidance Table:

(1) The contribution from acquisitions reflects only those acquisitions that have been completed.

(2) Organic revenue growth is defined as reported revenue growth adjusted for acquisitions and foreign currency translation.

(3) Acquisition-related amortization includes an estimate of $0.45-$0.65 for the impact of the Cognate acquisition and $0.05-$0.10 for other acquisitions completed in 2021 because the preliminary purchase price allocation has not been completed.

(4) These adjustments are related to the evaluation and integration of acquisitions, and primarily include transaction, advisory, and certain third-party integration costs, as well as certain costs associated with acquisition-related efficiency initiatives.

(5) These items primarily relate to charges of a) approximately $0.15 associated with U.S. and international tax legislation, and b) approximately $0.40 associated with debt extinguishment costs and the write-off of deferred financing costs related to debt refinancing.

(6) Venture capital and other strategic investment performance only includes recognized gains or losses. The Company does not forecast the future performance of these investments.

(7) Reconciliation of the current 2021 free cash flow guidance is as follows: Cash flow from operating activities of approximately $655 million, less capital expenditures of approximately $220 million, equates to free cash flow of approximately $435 million.

Webcast

Charles River has scheduled a live webcast on Tuesday, May 4th, at 9:00 a.m. ET to discuss matters relating to this press release. To participate, please go to ir.criver.com and select the webcast link. You can also find the associated slide presentation and reconciliations of GAAP financial measures to non-GAAP financial measures on the website.

Bank of America Health Care Conference Presentation

Charles River will virtually present at the Bank of America 2021 Health Care Conference, on Wednesday, May 12th, at 10:15 a.m. ET. Management will provide an overview of Charles River’s strategic focus and business developments.

A live webcast of the presentation will be available through a link that will be posted on ir.criver.com. A webcast replay will be accessible through the same website shortly after the presentation and will remain available for approximately two weeks.

Investor Day

Charles River will host a virtual Meeting with Management on Thursday, May 27th, beginning at 8:30 a.m. ET. Investors will have the opportunity to listen to a webcast of the virtual event through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.

Non-GAAP Reconciliations

The Company reports non-GAAP results in this press release, which exclude often-one-time charges and other items that are outside of normal operations. A reconciliation of GAAP to non-GAAP results is provided in the schedules at the end of this press release.

 

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, such as non-GAAP earnings per diluted share, which exclude the amortization of intangible assets, and other charges related to our acquisitions; expenses associated with evaluating and integrating acquisitions and divestitures, as well as fair value adjustments associated with contingent consideration; charges, gains, and losses attributable to businesses or properties we plan to close, consolidate, or divest; severance and other costs associated with our efficiency initiatives; the write-off of deferred financing costs and fees related to debt financing; third-party costs associated with the remediation of unauthorized access into our information systems detected in March 2019; the non-cash tax benefit related to our international financing structure; investment gains or losses associated with our venture capital and other strategic equity investments; and adjustments related to the recognition of deferred tax assets expected to be utilized as a result of changes to the our international financing structure. This press release also refers to our revenue in both a GAAP and non-GAAP basis: “organic revenue growth,” which we define as reported revenue growth adjusted for foreign currency translation, acquisitions, and divestitures. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. There are limitations in using non-GAAP financial measures, as they are not presented in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often-one-time charges, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions and divestitures (and in certain cases, the evaluation of such acquisitions and divestitures, whether or not ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities and their underlying associated costs, such as business acquisitions, generally occur periodically but on an unpredictable basis. We calculate non-GAAP integration costs to include third-party integration costs incurred post-acquisition. Presenting revenue on an organic basis allows investors to measure our revenue growth exclusive of acquisitions, divestitures, and foreign currency exchange fluctuations more clearly. Non-GAAP results also allow investors to compare the Company’s operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations presented in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. Reconciliations of the non-GAAP financial measures used in this press release to the most directly comparable GAAP financial measures are set forth in this press release, and can also be found on the Company’s website at ir.criver.com.

 

Caution Concerning Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding the impact of the COVID-19 pandemic; the projected future financial performance of Charles River and our specific businesses; the future demand for drug discovery and development products and services, including our expectations for future revenue trends; our expectations with respect to the impact of acquisitions completed in 2020 and 2021 on the Company, our service offerings, client perception, strategic relationships, revenue, revenue growth rates, and earnings; the development and performance of our services and products, including our investments in our portfolio; market and industry conditions including the outsourcing of services and spending trends by our clients; and Charles River’s future performance as delineated in our revised forward-looking guidance, and particularly our expectations with respect to revenue, the impact of foreign exchange, enhanced efficiency initiatives, and the assumptions surrounding the COVID-19 pandemic that form the basis for our revised annual guidance. Forward-looking statements are based on Charles River’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: the COVID-19 pandemic, its duration, its impact on our business, results of operations, financial condition, liquidity, business practices, operations, suppliers, third party service providers, clients, employees, industry, ability to meet future performance obligations, ability to efficiently implement advisable safety precautions, and internal controls over financial reporting; the COVID-19 pandemic’s impact on client demand, the global economy and financial markets; the ability to successfully integrate businesses we acquire (including Cognate BioServices and risks and uncertainties associated with Cognate BioServices products and services, which are in areas that the Company did not previously operate); the timing and magnitude of our share repurchases; negative trends in research and development spending, negative trends in the level of outsourced services, or other cost reduction actions by our clients; the ability to convert backlog to revenue; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; the impact of Brexit; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 17, 2021, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this press release except as required by law.

Estimates of COVID-19 Impact in 2020

In this press release, the Company has provided its estimates for the impact from the COVID-19 pandemic in 2020, including on the Company's revenue. These estimates were determined using methodologies and assumptions that vary depending on the specific reporting segment and situation. For the Research Models and Services segment, estimates were primarily based on comparisons to daily historical research model sales volumes prior to the COVID-19 pandemic and the subsequent reduction in research model order activity associated with our clients’ COVID-19 pandemic-related site closures and/or their reduced on-site activity, as well as our discussions with clients, particularly of our research model services and HemaCare businesses, with regard to revenue expectations and operational impacts from the COVID-19 pandemic. For the Discovery and Safety Assessment segment, estimates were based on multiple factors including, but not limited to, discussions with clients with regard to the cause of delays to discovery projects and safety assessment studies, location-specific actions to ensure employee safety in our facilities, the impact of remote versus in-person activities and services, and supply chain delays and other resource constraints. For the Manufacturing Support segment, estimates were based on multiple factors including, but not limited to, analysis of the sales impact due to the COVID-19 pandemic, assessments of idle instruments and the related revenue streams due to the inability to access clients’ sites, as well as discussions with clients with regard to their revenue expectations and operations. The estimated revenue loss related to COVID-19 was also expected to be partially offset by incremental work on clients’ COVID-19 programs. Because these estimates and assumptions involve risks and uncertainties, actual events and results may differ materially from these estimates and assumptions, and Charles River assumes no obligation and expressly disclaims any duty to update them.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

 
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
 
SCHEDULE 1
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(in thousands, except for per share data)
           
    Three Months Ended  
    March 27, 2021   March 28, 2020  
           
Service revenue

$

626,581

 

 

$

546,592

 

 
Product revenue

 

197,985

 

 

 

160,467

 

 
Total revenue

 

824,566

 

 

 

707,059

 

 
Costs and expenses:        
Cost of services provided (excluding amortization of intangible assets)

 

423,975

 

 

 

372,824

 

 
Cost of products sold (excluding amortization of intangible assets)

 

92,313

 

 

 

82,174

 

 
Selling, general and administrative

 

155,733

 

 

 

129,901

 

 
Amortization of intangible assets

 

28,842

 

 

 

27,879

 

 
Operating income

 

123,703

 

 

 

94,281

 

 
Other income (expense):        
Interest income

 

35

 

 

 

316

 

 
Interest expense

 

(29,719

)

 

 

(15,067

)

 
Other expense, net

 

(27,717

)

 

 

(24,071

)

 
Income from operations, before income taxes

 

66,302

 

 

 

55,459

 

 
Provision for income taxes

 

2,367

 

 

 

4,622

 

 
Net income

 

63,935

 

 

 

50,837

 

 
Less: Net income attributable to noncontrolling interests

 

2,405

 

 

 

68

 

 
Net income attributable to common shareholders

$

61,530

 

 

$

50,769

 

 
           
Earnings per common share        
Net income attributable to common shareholders:        
Basic

$

1.23

 

 

$

1.03

 

 
Diluted

$

1.20

 

 

$

1.02

 

 
           
Weighted-average number of common shares outstanding;        
Basic

 

49,980

 

 

 

49,189

 

 
Diluted

 

51,075

 

 

 

49,966

 

 
 
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
 
SCHEDULE 2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in thousands, except per share amounts)
       
       
  March 27, 2021   December 26, 2020
Assets      
Current assets:      
Cash and cash equivalents

$

465,411

 

 

$

228,424

 

Trade receivables, net of allowances for doubtful accounts of $7,278 and $6,702, respectively

 

610,566

 

 

 

617,740

 

Inventories

 

193,584

 

 

 

185,695

 

Prepaid assets

 

81,726

 

 

 

96,712

 

Other current assets

 

71,922

 

 

 

72,560

 

Total current assets

 

1,423,209

 

 

 

1,201,131

 

Property, plant and equipment, net

 

1,117,003

 

 

 

1,124,358

 

Operating lease right-of-use assets, net

 

197,668

 

 

 

178,220

 

Goodwill

 

1,890,630

 

 

 

1,809,168

 

Client relationships, net

 

712,384

 

 

 

721,505

 

Other intangible assets, net

 

83,181

 

 

 

66,094

 

Deferred tax assets

 

35,457

 

 

 

37,729

 

Other assets

 

349,431

 

 

 

352,626

 

Total assets

$

5,808,963

 

 

$

5,490,831

 

       
Liabilities, Redeemable Noncontrolling Interests and Equity      
Current liabilities:      
Current portion of long-term debt and finance leases

$

2,932

 

 

$

50,214

 

Accounts payable

 

127,129

 

 

 

122,475

 

Accrued compensation

 

164,748

 

 

 

206,823

 

Deferred revenue

 

213,032

 

 

 

207,942

 

Accrued liabilities

 

198,188

 

 

 

149,820

 

Other current liabilities

 

97,347

 

 

 

102,477

 

Total current liabilities

 

803,376

 

 

 

839,751

 

Long-term debt, net and finance leases

 

2,202,334

 

 

 

1,929,571

 

Operating lease right-of-use liabilities

 

173,015

 

 

 

155,595

 

Deferred tax liabilities

 

207,011

 

 

 

217,031

 

Other long-term liabilities

 

207,008

 

 

 

205,215

 

Total liabilities

 

3,592,744

 

 

 

3,347,163

 

Redeemable noncontrolling interests

 

28,035

 

 

 

25,499

 

Equity:      
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding

 

-

 

 

 

-

 

Common stock, $0.01 par value; 120,000 shares authorized; 50,350 shares issued and 50,216 shares outstanding as of March 27, 2021, and 49,767 shares issued and outstanding as of December 26, 2020

 

504

 

 

 

498

 

Additional paid-in capital

 

1,659,524

 

 

 

1,627,564

 

Retained earnings

 

686,944

 

 

 

625,414

 

Treasury stock, at cost, 134 and 0 shares, as of March 27, 2021 and December 26, 2020, respectively

 

(36,028

)

 

 

-

 

Accumulated other comprehensive loss

 

(127,017

)

 

 

(138,874

)

Total equity attributable to common shareholders

 

2,183,927

 

 

 

2,114,602

 

Noncontrolling interest

 

4,257

 

 

 

3,567

 

Total equity

 

2,188,184

 

 

 

2,118,169

 

Total liabilities, redeemable noncontrolling interests and equity

$

5,808,963

 

 

$

5,490,831

 

 
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
 
SCHEDULE 3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(in thousands)
       
  Three Months Ended
  March 27, 2021   March 28, 2020
Cash flows relating to operating activities      
Net income

$

63,935

 

 

$

50,837

 

Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization

 

61,508

 

 

 

57,260

 

Stock-based compensation

 

13,189

 

 

 

10,960

 

Debt extinguishment and financing costs

 

26,907

 

 

 

-

 

Deferred income taxes

 

(9,125

)

 

 

(2,973

)

Loss on venture capital and strategic equity investments, net

 

16,719

 

 

 

12,035

 

Other, net

 

496

 

 

 

10,495

 

Changes in assets and liabilities:      
Trade receivables, net

 

5,598

 

 

 

(32,136

)

Inventories

 

(11,404

)

 

 

4,076

 

Accounts payable

 

9,622

 

 

 

(10,003

)

Accrued compensation

 

(37,360

)

 

 

(45,245

)

Deferred revenue

 

5,006

 

 

 

6,065

 

Customer contract deposits

 

(5,446

)

 

 

4,454

 

Other assets and liabilities, net

 

30,584

 

 

 

2,765

 

Net cash provided by operating activities

 

170,229

 

 

 

68,590

 

Cash flows relating to investing activities      
Acquisition of businesses and assets, net of cash acquired

 

(94,197

)

 

 

(382,250

)

Capital expenditures

 

(28,030

)

 

 

(25,721

)

Purchases of investments and contributions to venture capital investments

 

(16,550

)

 

 

(7,121

)

Proceeds from sale of investments

 

-

 

 

 

2,504

 

Other, net

 

781

 

 

 

(1,097

)

Net cash used in investing activities

 

(137,996

)

 

 

(413,685

)

Cash flows relating to financing activities      
Proceeds from long-term debt and revolving credit facility

 

1,954,011

 

 

 

1,409,793

 

Proceeds from exercises of stock options

 

19,612

 

 

 

22,608

 

Payments on long-term debt, revolving credit facility, and finance lease obligations

 

(1,714,195

)

 

 

(925,109

)

Purchase of treasury stock

 

(36,028

)

 

 

(23,675

)

Payment of debt extinguishment and financing costs

 

(28,680

)

 

 

-

 

Other, net

 

-

 

 

 

(4,405

)

Net cash provided by financing activities

 

194,720

 

 

 

479,212

 

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

 

10,953

 

 

 

290

 

Net change in cash, cash equivalents, and restricted cash

 

237,906

 

 

 

134,407

 

Cash, cash equivalents, and restricted cash, beginning of period

 

233,119

 

 

 

240,046

 

Cash, cash equivalents, and restricted cash, end of period

$

471,025

 

 

$

374,453

 

       
Supplemental cash flow information:      
Cash and cash equivalents

$

465,411

 

 

$

372,433

 

Restricted cash included in Other current assets

 

4,012

 

 

 

444

 

Restricted cash included in Other assets

 

1,602

 

 

 

1,576

 

Cash, cash equivalents, and restricted cash, end of period

$

471,025

 

 

$

374,453

 

 
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
         
SCHEDULE 4
RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)(1)
(in thousands, except percentages)
         
    Three Months Ended
    March 27, 2021   March 28, 2020
Research Models and Services        
Revenue  

$

176,910

 

 

$

145,996

 

Operating income  

 

44,935

 

 

 

27,373

 

Operating income as a % of revenue  

 

25.4

%

 

 

18.7

%

Add back:        
Amortization related to acquisitions  

 

5,339

 

 

 

5,652

 

Severance  

 

7

 

 

 

(9

)

Acquisition related adjustments (2)  

 

456

 

 

 

285

 

Site consolidation costs, impairments and other items  

 

-

 

 

 

229

 

Total non-GAAP adjustments to operating income  

$

5,802

 

 

$

6,157

 

Operating income, excluding non-GAAP adjustments  

$

50,737

 

 

$

33,530

 

Non-GAAP operating income as a % of revenue  

 

28.7

%

 

 

23.0

%

         
Depreciation and amortization  

$

9,679

 

 

$

8,752

 

Capital expenditures  

$

2,983

 

 

$

5,412

 

         
Discovery and Safety Assessment        
Revenue  

$

501,178

 

 

$

438,683

 

Operating income  

 

90,949

 

 

 

72,283

 

Operating income as a % of revenue  

 

18.1

%

 

 

16.5

%

Add back:        
Amortization related to acquisitions  

 

22,648

 

 

 

23,007

 

Severance  

 

412

 

 

 

83

 

Acquisition related adjustments (2)  

 

5,270

 

 

 

1,289

 

Site consolidation costs, impairments and other items  

 

147

 

 

 

-

 

Total non-GAAP adjustments to operating income  

$

28,477

 

 

$

24,379

 

Operating income, excluding non-GAAP adjustments  

$

119,426

 

 

$

96,662

 

Non-GAAP operating income as a % of revenue  

 

23.8

%

 

 

22.0

%

         
Depreciation and amortization  

$

44,608

 

 

$

41,330

 

Capital expenditures  

$

17,040

 

 

$

14,729

 

         
Manufacturing Support        
Revenue  

$

146,478

 

 

$

122,380

 

Operating income  

 

49,437

 

 

 

41,112

 

Operating income as a % of revenue  

 

33.8

%

 

 

33.6

%

Add back:        
Amortization related to acquisitions  

 

2,214

 

 

 

2,247

 

Severance  

 

294

 

 

 

256

 

Acquisition related adjustments (2)  

 

42

 

 

 

2

 

Site consolidation costs, impairments and other items  

 

40

 

 

 

-

 

Total non-GAAP adjustments to operating income  

$

2,590

 

 

$

2,505

 

Operating income, excluding non-GAAP adjustments  

$

52,027

 

 

$

43,617

 

Non-GAAP operating income as a % of revenue  

 

35.5

%

 

 

35.6

%

         
Depreciation and amortization  

$

6,569

 

 

$

6,366

 

Capital expenditures  

$

7,110

 

 

$

5,161

 

         
Unallocated Corporate Overhead  

$

(61,618

)

 

$

(46,487

)

Add back:        
Severance  

 

(151

)

 

 

-

 

Acquisition related adjustments (2)  

 

10,560

 

 

 

6,983

 

Other items (3)  

 

-

 

 

 

(287

)

Total non-GAAP adjustments to operating expense  

$

10,409

 

 

$

6,696

 

Unallocated corporate overhead, excluding non-GAAP adjustments  

$

(51,209

)

 

$

(39,791

)

         
Total        
Revenue  

$

824,566

 

 

$

707,059

 

Operating income  

 

123,703

 

 

 

94,281

 

Operating income as a % of revenue  

 

15.0

%

 

 

13.3

%

Add back:        
Amortization related to acquisitions  

 

30,201

 

 

 

30,906

 

Severance  

 

562

 

 

 

330

 

Acquisition related adjustments (2)  

 

16,328

 

 

 

8,559

 

Site consolidation costs, impairments and other items (3)  

 

187

 

 

 

(58

)

Total non-GAAP adjustments to operating income  

$

47,278

 

 

$

39,737

 

Operating income, excluding non-GAAP adjustments  

$

170,981

 

 

$

134,018

 

Non-GAAP operating income as a % of revenue  

 

20.7

%

 

 

19.0

%

         
Depreciation and amortization  

$

61,508

 

 

$

57,260

 

Capital expenditures  

$

28,030

 

 

$

25,721

 

(1)

  Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2)

  These adjustments are related to the evaluation and integration of acquisitions, which primarily include transaction, third-party integration, and certain compensation costs, and fair value adjustments associated with contingent consideration.

(3)

  Other items relate to third-party costs, net of insurance reimbursements, incurred during the three months ended March 28, 2020 associated with the remediation of the unauthorized access into the Company's information systems which was detected in March 2019.
 
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
 
SCHEDULE 5
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)(1)
(in thousands, except per share data)
       
  Three Months Ended
  March 27, 2021   March 28, 2020
       
Net income attributable to common shareholders

$

61,530

 

 

$

50,769

 

Add back:      
Non-GAAP adjustments to operating income (Refer to previous schedule)

 

47,278

 

 

 

39,737

 

Write-off of deferred financing costs and fees related to debt financing

 

25,979

 

 

 

-

 

Venture capital and strategic equity investment losses, net

 

16,719

 

 

 

12,035

 

Other (2)

 

(2,370

)

 

 

-

 

Tax effect of non-GAAP adjustments:      
Non-cash tax provision related to international financing structure (3)

 

1,035

 

 

 

1,073

 

Tax effect of the remaining non-GAAP adjustments

 

(21,013

)

 

 

(11,804

)

Net income attributable to common shareholders, excluding non-GAAP adjustments

$

129,158

 

 

$

91,810

 

       
Weighted average shares outstanding - Basic

 

49,980

 

 

 

49,189

 

Effect of dilutive securities:      
Stock options, restricted stock units and performance share units

 

1,095

 

 

 

777

 

Weighted average shares outstanding - Diluted

 

51,075

 

 

 

49,966

 

       
Earnings per share attributable to common shareholders:      
Basic

$

1.23

 

 

$

1.03

 

Diluted

$

1.20

 

 

$

1.02

 

       
Basic, excluding non-GAAP adjustments

$

2.58

 

 

$

1.87

 

Diluted, excluding non-GAAP adjustments

$

2.53

 

 

$

1.84

 

(1)

Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2)

This adjustment relates to the gain on an immaterial divestiture which occurred in the three months ended March 27, 2021.

(3)

This adjustment relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure.
 
RECONCILIATION OF GAAP REVENUE GROWTH

TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED) (1)

                 
                 
Three Months Ended March 27, 2021   Total CRL   RMS Segment   DSA Segment   MS Segment
                 
Revenue growth, reported  

16.6 %

 

21.2 %

 

14.2 %

 

19.7 %

Increase due to foreign exchange  

(2.9)%

 

(4.2)%

 

(2.3)%

 

(4.1)%

Contribution from acquisitions (2)  

(0.7)%

 

(2.2)%

 

(0.3)%

 

- %

Non-GAAP revenue growth, organic (3)  

13.0 %

 

14.8 %

 

11.6 %

 

15.6 %

(1)

  Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2)

  The contribution from acquisitions reflects only completed acquisitions.

(3)

  Organic revenue growth is defined as reported revenue growth adjusted for acquisitions and foreign exchange.

 

Contacts

Investor Contacts:
Todd Spencer
Corporate Vice President,
Investor Relations
781.222.6455
todd.spencer@crl.com

Media Contact:
Amy Cianciaruso
Corporate Vice President,
Public Relations
781.222.6168
amy.cianciaruso@crl.com

 
 

Source: Charles River Laboratories International, Inc.

Back to news